Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Edesa Biotech Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
EDSA
Nasdaq
8731
https://www.edesabiotech.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Edesa Biotech Inc
Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference
- Apr 11th, 2024 1:00 pm
Edesa Biotech to Participate in Upcoming Investor Conferences
- Apr 2nd, 2024 1:00 pm
Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference
- Mar 21st, 2024 8:30 pm
Edesa Biotech to Participate in Barclays Global Healthcare Conference
- Mar 7th, 2024 12:45 pm
Edesa Biotech to Participate in Upcoming Dermatology Meetings
- Mar 4th, 2024 9:30 pm
EDSA: Development of EB05 in ARDS Continues…
- Feb 15th, 2024 1:21 pm
Edesa Biotech Reports Fiscal 1st Quarter 2024 Results
- Feb 9th, 2024 9:15 pm
Edesa Biotech to Participate in Dermatology Summit and JP Morgan Week
- Jan 4th, 2024 9:15 pm
EDSA: Updated Phase 3 Protocol for EB05 Trial Approved by Canadian Regulators…
- Jan 2nd, 2024 4:06 pm
Edesa Biotech Reports Fiscal Year 2023 Results
- Dec 15th, 2023 9:10 pm
Edesa Biotech Reports Final Phase 2b Results for Dermatitis Study
- Nov 20th, 2023 9:05 pm
Edesa Biotech to Present at Dermatology Drug Development Summit
- Oct 26th, 2023 8:05 pm
Regulators Approve Updated Phase 3 Trial Design for Edesa Biotech’s ARDS Drug
- Oct 25th, 2023 1:10 pm
EDSA: Secures up to CAD$23 Million to Fund Development of EB05…
- Oct 19th, 2023 1:15 pm
Edesa Biotech Secures $10 Million Credit Facility with Company Founder
- Oct 12th, 2023 4:15 pm
Edesa Biotech to Receive Up To C$23 Million in Funding from Federal Government
- Oct 12th, 2023 4:10 pm
Edesa Biotech Announces One-for-Seven Reverse Share Split
- Oct 10th, 2023 1:00 pm
Edesa Biotech Publishes Phase 2 Substudy Results of ARDS Drug Candidate
- Sep 28th, 2023 12:15 pm
EDSA: EB05 Inhibits Inflammation Initiated by Multiple Pathogens In Vitro…
- Aug 16th, 2023 3:40 pm
Edesa Biotech Reports Fiscal Third Quarter 2023 Results
- Aug 9th, 2023 8:15 pm
Scroll